Zynerba Pharmaceuticals Receives a Buy from H.C. Wainwright

By Carrie Williams

H.C. Wainwright analyst Corey Davis reiterated a Buy rating on Zynerba Pharmaceuticals (NASDAQ: ZYNE) today. The company’s shares opened today at $14.44.

According to TipRanks.com, Davis is a 1-star analyst with an average return of -3.0% and a 36.9% success rate. Davis covers the Healthcare sector, focusing on stocks such as Aquinox Pharmaceuticals, Infotek Pharmaceuticals, and Pacira Pharmaceuticals.

Zynerba Pharmaceuticals has an analyst consensus of Strong Buy.

The company has a one year high of $21.56 and a one year low of $4.64. Currently, Zynerba Pharmaceuticals has an average volume of 248.5K.

Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs. Its clinical programs include synthetic cannabinoid therapeutics and patch and gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.